Additional biomarkers, such as p16/Ki-67 immunohistochemistry or DNA methylation assays, should also be considered to further enhance diagnostic precision and support the development of more personalized cervical cancer screening protocols. This evidence concerns the gene CDKN2A and cervical cancer.